Recently, the FDA granted accelerated approval to the anti-PD-1 antibody nivolumab in combination with the anti-CTLA-4 ipilimumab for the treatment of patients with HCC previously treated with sorafenib [18]. Here, CTLA4 is linked to hepatocellular carcinoma.